Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
AUPH
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.08
vs -0.25
Q3.23
N/A
-0.09
vs -0.06
Q4.23
N/A
-0.19
vs -0.18
Q1.24
N/A
-0.03
vs -0.18
Q2.24
+125%
0.02
vs -0.08
Q3.24
+211%
0.1
vs -0.09
Q4.24
+147%
0.09
vs -0.19
Q1.25
+633%
0.16
vs -0.03
Q2.25
+620%
0.14
vs 0.02
Q3.25
+40%
0.14
vs 0.1
Sales Growth
YoY
Current
Estimates
Q2.23
+47%
41.5M vs 28.2M
Q3.23
-2%
54.5M vs 55.8M
Q4.23
+59%
45.1M vs 28.4M
Q1.24
+46%
50.3M vs 34.4M
Q2.24
+38%
57.2M vs 41.5M
Q3.24
+24%
67.8M vs 54.5M
Q4.24
+33%
59.9M vs 45.1M
Q1.25
+24%
62.5M vs 50.3M
Q2.25
+12%
64.3M vs 57.2M
Q3.25
-5%
64.5M vs 67.8M
Return on Equity
QoQ
Q2.23
-3%
-0.03
vs -0.07
Q3.23
-3%
-0.03
vs -0.03
Q4.23
-7%
-0.07
vs -0.03
Q1.24
-3%
-0.03
vs -0.07
Q2.24
+0%
0
vs -0.03
Q3.24
+4%
0.04
vs 0
Q4.24
+0%
0
vs 0.04
Q1.25
+7%
0.07
vs 0
Institutionnal Ownership
QoQ
Q2.23
219
219
vs 202
8%
Q3.23
217
217
vs 219
-1%
Q4.23
210
210
vs 217
-3%
Q1.24
198
198
vs 210
-6%
Q2.24
181
181
vs 198
-9%
Q3.24
197
197
vs 181
9%
Q4.24
215
215
vs 197
9%
Q1.25
222
222
vs 215
3%
businesswire.com
6 hours ago
https://www.marketscreener.com
9 hours ago
zacks.com
10 hours ago
proactiveinvestors.com
14 hours ago
businesswire.com
17 hours ago
Quote Panel
Key Metrics
Forecast
392%2026-Revenue
346%2026-EPS
-943%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Oppenheimer
upgradePrevious: Not converted
2021-12-10
Now: Outperform
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
NASDAQ
-0.17Â ( -1.97%)
Pre-market 8.42$-0.05 (-0.59%)
Relative Strenght
81
Volume Buzz
48%
Earning Acce
No
Dist 52w H.
21%Relative Strength
AUPH
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|